130 related articles for article (PubMed ID: 15961782)
21. ACOG Committee Opinion. Aromatase inhibitors in gynecologic practice.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Aug; 112(2 Pt 1):405-7. PubMed ID: 18669744
[No Abstract] [Full Text] [Related]
22. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
[TBL] [Abstract][Full Text] [Related]
23. Postmenopausal hormone receptor-positive advanced breast cancer.
Connolly RM; Stearns V
Oncology (Williston Park); 2013 Jun; 27(6):571-2, 574, 576 passim. PubMed ID: 23909072
[No Abstract] [Full Text] [Related]
24. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
25. [New development in treatment of breast cancer. I. New development in pre-operative hormone therapy].
Sato N
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2548-50. PubMed ID: 20104675
[No Abstract] [Full Text] [Related]
26. Update on aromatase inhibitors in breast cancer.
Gould RE; Garcia AA
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
[TBL] [Abstract][Full Text] [Related]
27. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM
Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
[TBL] [Abstract][Full Text] [Related]
28. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
29. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
30. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
31. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
[TBL] [Abstract][Full Text] [Related]
32. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Booth CM; Pater JL; Goss PE
Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
[No Abstract] [Full Text] [Related]
33. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
36. The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Jonat W; Mundhenke C
Cancer Invest; 2007 Feb; 25(1):14-8. PubMed ID: 17364552
[TBL] [Abstract][Full Text] [Related]
37. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
38. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Barginear M; Clotfelter A; Poznak CV
Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
40. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
